Cargando…

Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review

Most patients with metastatic hormone sensitive prostate cancer will progress to metastatic castration-resistant prostate cancer (mCRPC); Finding a highly effective, safe treatment with low recurrence rate has important clinical implications. Herein, we present a case of a 65-year-old man with castr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Dongsheng, Su, Wen, Zeng, Liang, Hu, Guoqian, Tang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206126/
https://www.ncbi.nlm.nih.gov/pubmed/37234981
http://dx.doi.org/10.3389/fonc.2023.1177941
_version_ 1785046159097593856
author Zhao, Dongsheng
Su, Wen
Zeng, Liang
Hu, Guoqian
Tang, Jin
author_facet Zhao, Dongsheng
Su, Wen
Zeng, Liang
Hu, Guoqian
Tang, Jin
author_sort Zhao, Dongsheng
collection PubMed
description Most patients with metastatic hormone sensitive prostate cancer will progress to metastatic castration-resistant prostate cancer (mCRPC); Finding a highly effective, safe treatment with low recurrence rate has important clinical implications. Herein, we present a case of a 65-year-old man with castration-resistant prostate cancer treated by multi-protocol exploration. Magnetic resonance imaging (MRI) revealed prostate cancer invading the bladder, seminal vesicle glands, and peritoneum with pelvic lymph node metastasis. Transrectal B ultrasound puncture of prostate tissue was performed, and the pathological diagnosis was prostatic adenocarcinoma. CTC (Circulating tumor cell) gene test was performed in peripheral blood, and the result showed BRCA1 gene mutation. The patient died of tumor complications after trying docetaxel combined with cisplatin chemotherapy, PARP inhibitor (nilaparib), PD-1 inhibitor (tislelizumab) and other treatments. This patient showed that the selection of an individualized combination chemotherapy regimen based on genetic testing results benefited the patient’s tumor control. When choosing a treatment regimen, problems such as failure to respond to re-chemotherapy and resistance to nilaparib may lead to deterioration of the condition.
format Online
Article
Text
id pubmed-10206126
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102061262023-05-25 Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review Zhao, Dongsheng Su, Wen Zeng, Liang Hu, Guoqian Tang, Jin Front Oncol Oncology Most patients with metastatic hormone sensitive prostate cancer will progress to metastatic castration-resistant prostate cancer (mCRPC); Finding a highly effective, safe treatment with low recurrence rate has important clinical implications. Herein, we present a case of a 65-year-old man with castration-resistant prostate cancer treated by multi-protocol exploration. Magnetic resonance imaging (MRI) revealed prostate cancer invading the bladder, seminal vesicle glands, and peritoneum with pelvic lymph node metastasis. Transrectal B ultrasound puncture of prostate tissue was performed, and the pathological diagnosis was prostatic adenocarcinoma. CTC (Circulating tumor cell) gene test was performed in peripheral blood, and the result showed BRCA1 gene mutation. The patient died of tumor complications after trying docetaxel combined with cisplatin chemotherapy, PARP inhibitor (nilaparib), PD-1 inhibitor (tislelizumab) and other treatments. This patient showed that the selection of an individualized combination chemotherapy regimen based on genetic testing results benefited the patient’s tumor control. When choosing a treatment regimen, problems such as failure to respond to re-chemotherapy and resistance to nilaparib may lead to deterioration of the condition. Frontiers Media S.A. 2023-05-10 /pmc/articles/PMC10206126/ /pubmed/37234981 http://dx.doi.org/10.3389/fonc.2023.1177941 Text en Copyright © 2023 Zhao, Su, Zeng, Hu and Tang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhao, Dongsheng
Su, Wen
Zeng, Liang
Hu, Guoqian
Tang, Jin
Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review
title Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review
title_full Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review
title_fullStr Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review
title_full_unstemmed Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review
title_short Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review
title_sort multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with brca mutations: a case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206126/
https://www.ncbi.nlm.nih.gov/pubmed/37234981
http://dx.doi.org/10.3389/fonc.2023.1177941
work_keys_str_mv AT zhaodongsheng multiprotocolexploratorytreatmentformetastaticcastrationresistantprostatecancerwithbrcamutationsacasereportandliteraturereview
AT suwen multiprotocolexploratorytreatmentformetastaticcastrationresistantprostatecancerwithbrcamutationsacasereportandliteraturereview
AT zengliang multiprotocolexploratorytreatmentformetastaticcastrationresistantprostatecancerwithbrcamutationsacasereportandliteraturereview
AT huguoqian multiprotocolexploratorytreatmentformetastaticcastrationresistantprostatecancerwithbrcamutationsacasereportandliteraturereview
AT tangjin multiprotocolexploratorytreatmentformetastaticcastrationresistantprostatecancerwithbrcamutationsacasereportandliteraturereview